0
By Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC
Of the recurring themes that tend to circulate in the drug development discourse, China is a uniquely fascinating and polarizing subject. Perspectives vary tremendously, ranging from those who view China as an expansive opportunity of which we are just beginning to scratch the surface, to those who see China as the single largest single threat to the health and viability of the US and European biotechnology industries.
In this blog, I’d like to offer a perspective from the lens of a CEO of US small biotech company, in…